share_log
Hi,
moomoo ID:0
Log Out
English
Back
  • English
  • 中文繁体
  • 中文简体

Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease

MT Newswires ·  09/28 11:30

11:29 PM EDT, 09/27/2022 (MT Newswires) -- Swissmedic granted Vifor Fresenius Medical Care Renal Pharma marketing authorization for Tavneos in combination with rituximab or cyclophosphamide for the treatment of two main forms of antineutrophil cytoplasmic antibody-associated vasculitis, a rare blood vessel disease.

Tavneos was developed by ChemoCentryx (2CX.F), while the joint venture between CSL Vifor (VIFN.SW), formerly known as Vifor Pharma, and Fresenius Medical Care (FME.F) owns exclusive rights to commercialize the orally administered therapy outside the US, according to a Tuesday release.

CSL Vifor expects the commercialization of Tavneos in the coming weeks.

ChemoCentryx gained over 1%, CSL Vifor lost marginally and Fresenius Medical Care was down over 3% on Tuesday's close.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.